Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glycation End Products, Advanced | 8 | 2021 | 125 | 3.770 |
Why?
|
| Breast Neoplasms | 11 | 2021 | 1536 | 1.750 |
Why?
|
| Proto-Oncogene Proteins c-ets | 7 | 2011 | 79 | 1.510 |
Why?
|
| Diet | 4 | 2021 | 514 | 1.420 |
Why?
|
| Prostatic Neoplasms | 4 | 2014 | 778 | 1.000 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 3 | 2013 | 65 | 0.790 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2013 | 756 | 0.730 |
Why?
|
| Neoplasms | 5 | 2016 | 1667 | 0.710 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 179 | 0.660 |
Why?
|
| Receptors, Estrogen | 2 | 2020 | 142 | 0.660 |
Why?
|
| Breast | 1 | 2020 | 137 | 0.660 |
Why?
|
| Life Style | 2 | 2018 | 338 | 0.660 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 235 | 0.630 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 562 | 0.600 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.530 |
Why?
|
| Cell Movement | 6 | 2013 | 630 | 0.490 |
Why?
|
| Cell Line, Tumor | 11 | 2018 | 1851 | 0.460 |
Why?
|
| Health Status Disparities | 1 | 2016 | 326 | 0.430 |
Why?
|
| MicroRNAs | 4 | 2013 | 447 | 0.420 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 508 | 0.370 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 282 | 0.340 |
Why?
|
| Humans | 28 | 2022 | 68618 | 0.330 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 61 | 0.300 |
Why?
|
| Oncogenes | 1 | 2008 | 71 | 0.290 |
Why?
|
| Cancer Survivors | 2 | 2020 | 146 | 0.290 |
Why?
|
| Idoxuridine | 1 | 2006 | 4 | 0.280 |
Why?
|
| Endodeoxyribonucleases | 1 | 2006 | 8 | 0.280 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 498 | 0.260 |
Why?
|
| Genetic Therapy | 1 | 2008 | 291 | 0.260 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 111 | 0.260 |
Why?
|
| Pyrimidines | 1 | 2006 | 178 | 0.250 |
Why?
|
| Phenotype | 5 | 2013 | 947 | 0.240 |
Why?
|
| Postmenopause | 2 | 2021 | 93 | 0.220 |
Why?
|
| Female | 12 | 2021 | 38074 | 0.210 |
Why?
|
| Neisseria meningitidis | 1 | 2022 | 10 | 0.210 |
Why?
|
| Meningococcal Infections | 1 | 2022 | 5 | 0.210 |
Why?
|
| Meningococcal Vaccines | 1 | 2022 | 17 | 0.210 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 17 | 0.190 |
Why?
|
| Fasting | 1 | 2021 | 75 | 0.190 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 21 | 0.190 |
Why?
|
| Immunization Schedule | 1 | 2021 | 25 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 46 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2018 | 2689 | 0.190 |
Why?
|
| Risk Factors | 3 | 2020 | 5731 | 0.190 |
Why?
|
| Aged | 6 | 2021 | 14862 | 0.170 |
Why?
|
| Lysine | 1 | 2020 | 96 | 0.170 |
Why?
|
| Middle Aged | 7 | 2021 | 21147 | 0.160 |
Why?
|
| Neoplasm Metastasis | 3 | 2013 | 306 | 0.160 |
Why?
|
| Tamoxifen | 1 | 2018 | 62 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 369 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.150 |
Why?
|
| Disease Progression | 3 | 2013 | 1038 | 0.150 |
Why?
|
| Male | 7 | 2021 | 37321 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 282 | 0.150 |
Why?
|
| United Kingdom | 3 | 2022 | 152 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1342 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2020 | 867 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 507 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 332 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 800 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2020 | 3705 | 0.130 |
Why?
|
| Diet, Western | 1 | 2015 | 17 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1174 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 118 | 0.120 |
Why?
|
| Animals | 8 | 2015 | 20881 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 658 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 183 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 213 | 0.110 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.110 |
Why?
|
| Peroxiredoxins | 1 | 2013 | 34 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2011 | 312 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2013 | 1174 | 0.100 |
Why?
|
| Orchiectomy | 1 | 2012 | 25 | 0.100 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 25 | 0.100 |
Why?
|
| Androgens | 1 | 2012 | 41 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 34 | 0.100 |
Why?
|
| Prostate | 1 | 2012 | 116 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 349 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 226 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2015 | 718 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2011 | 75 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7029 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2021 | 249 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2015 | 902 | 0.090 |
Why?
|
| Gene Silencing | 2 | 2010 | 137 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 135 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2011 | 305 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 97 | 0.090 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 44 | 0.090 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 14 | 0.080 |
Why?
|
| Adolescent | 4 | 2022 | 8912 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2008 | 84 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 181 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1076 | 0.070 |
Why?
|
| Mice | 5 | 2015 | 8474 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 261 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 299 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2007 | 161 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 320 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2011 | 753 | 0.070 |
Why?
|
| Base Pair Mismatch | 1 | 2006 | 12 | 0.070 |
Why?
|
| CpG Islands | 1 | 2006 | 51 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2006 | 234 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 176 | 0.070 |
Why?
|
| Actins | 1 | 2007 | 249 | 0.060 |
Why?
|
| Young Adult | 3 | 2021 | 5717 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 246 | 0.060 |
Why?
|
| Transfection | 1 | 2007 | 782 | 0.060 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.060 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 11 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 1752 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2673 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2013 | 1664 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 6 | 0.050 |
Why?
|
| Inflammation | 1 | 2007 | 1030 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 21 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 48 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 56 | 0.050 |
Why?
|
| South Africa | 1 | 2020 | 45 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2021 | 93 | 0.050 |
Why?
|
| Women's Health | 1 | 2021 | 148 | 0.050 |
Why?
|
| Viral Load | 1 | 2021 | 127 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 792 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 21403 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 267 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 931 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1738 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2550 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2279 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 2015 | 54 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2007 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 454 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 561 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 489 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 710 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3259 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 268 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 30 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 18 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Multigene Family | 1 | 2013 | 93 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 62 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 132 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 304 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2800 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2011 | 31 | 0.020 |
Why?
|
| Homeostasis | 1 | 2013 | 291 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 567 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1173 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 615 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 284 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 93 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 948 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1033 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2009 | 37 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 40 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2009 | 26 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2009 | 26 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 160 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 2791 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 1641 | 0.010 |
Why?
|